Choi Ji U, Kim Yeongrin, Lee Da Yeon, Park Jin Song, Jeun Moonjung, Lee Heung Kyoung, Park Chi Hoon
Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
Biomark Res. 2025 Jan 3;13(1):1. doi: 10.1186/s40364-024-00703-9.
Although chimeric antigen receptor (CAR) T cell therapy has shown remarkable efficacy against leukemic cells, it still has critical limitations. CAR macrophage has been regarded as a potential alternative to CAR T cells. However, due to the difficulties in gene transduction into macrophages, the production of primary human CAR macrophages from peripheral blood mononuclear cells (PBMC) using lentivirus is highly challenging. Here, we report on how to generate CAR macrophages from human PBMC with lentiviral particles. Using our lentiviral protocol, we produced functional CAR macrophages to lyse and phagocytose target cancer cells efficiently.
尽管嵌合抗原受体(CAR)T细胞疗法已显示出对白血病细胞的显著疗效,但它仍存在关键局限性。CAR巨噬细胞已被视为CAR T细胞的一种潜在替代方案。然而,由于将基因转导至巨噬细胞存在困难,使用慢病毒从外周血单核细胞(PBMC)中产生原代人CAR巨噬细胞极具挑战性。在此,我们报告如何利用慢病毒颗粒从人PBMC中生成CAR巨噬细胞。通过我们的慢病毒方案,我们制备出了能有效裂解和吞噬靶癌细胞的功能性CAR巨噬细胞。